computer-generated randomisation sequence sas version 9.1 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
computer-generated randomisation sequence sas version 9.1
Computer Generated Randomisation Sequence Sas Version 9.1, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomization+scheme/computer+generated+randomization+scheme+sas+version+9+1+3/pmc07271646-648-20-23
Average 90 stars, based on 1 article reviews
Computer Generated Randomisation Sequence Sas Version 9.1, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomization+scheme/computer+generated+randomization+scheme+sas+version+9+1+3/pmc07271646-648-20-23
Average 90 stars, based on 1 article reviews
computer-generated randomisation sequence sas version 9.1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Construct:Article Title: Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Number: 82170562; Capital's Funds for Health Improvement and Research, Grant/Award Number: 202224093; Clinical Key Project of Peking University Third Hospital, Grant/ Award Number: Y7649305; Talent Incubation Fund of Peking University Third Hospital, Grant/Award Number: Y7649306 Abstract Background: Due to general unavailability and common side effects of tetracycline, the clinical application of bismuth quadruple therapy (BQT) is greatly limited.. Whether amoxicillin can replace tetracycline in BQT remains unknown.. This study aimed to compare the eradication rate, safety and compliance between amoxicillincontaining and tetracyclinecontaining BQT as a firstline regimen for Helicobacter pylori eradication. Article Title: A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Article Snippet: Funding information This study was supported by the Key Laboratory for Helicobacter pylori Infection and Upper Gastrointestinal Diseases in Beijing (No. BZ0371), the National Natural Science Foundation of China (No. 81670605), and the Clinical Key Projects of Peking University Third Hospital (No. Y76493-05) and AstraZeneca.. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.. Abstract Background: Favorable outcomes in treating H pylori infection using “dual therapy (proton pump inhibitor and amoxicillin four times daily)” have attracted widespread attention. Article Title: Recurrence of Helicobacter pylori infection and the affecting factors: A follow-up study. Article Snippet: study Recurrence of H. pylori infection Li Ya ZHOU, Zhi Qiang SONG, Yan XUE, Xiao LI, Yan Qing LI, Jia Ming QIAN Department of Gastroenterology, Peking University Third Hospital, Beijing, Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong Province, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China Correspondence to: Li Ya ZHOU, Department of Gastroenterology, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China.. Email: zhouliya123456@163.com Conflict of interest: None.. ABSTRACT OBJECTIVE: Recurrence of Helicobacter pylori (H. pylori) infection weakens the protective effect and long-term prognosis of eradication. Article Title: Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Article Snippet: *Department of Gastroenterology, Peking University Third Hospital, Beijing, China, State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention, National Institute for Communicable Disease Control and Prevention, Beijing, China, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, China, Department of Gastroenterology, Qilu Hospital of Shandong University, Shandong, China, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China Article Title: Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial Article Snippet: A Article Title: Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial Article Snippet: Methods The Optimizing Early Enteral Nutrition in Severe Stroke (OPENS) study was a multicentre, investigatorinitiated, prospective, open-label, randomised controlled trial, with blinded outcome assessment, in 16 tertiary and district general hospitals in the west of China.. Adult patients with acute severe ischaemic or haemorrhagic stroke (Glasgow Coma Scale score ≤12 or National Institutes of Health Stroke Scale score ≥11 on admission) who were expected to receive enteral nutrition for more than 7 days were randomly assigned (1:1:1) to full enteral nutrition (70–100% of estimated caloric requirements), modified full enteral nutrition (full enteral nutrition plus prokinetic agents), or hypocaloric enteral nutrition (40–60% of estimated caloric requirements) via a centralised web-based randomisation system.. The assigned nutrition was initiated within 24 h after enrolment and continued for 7 days. Blocking Assay:Article Title: Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Number: 82170562; Capital's Funds for Health Improvement and Research, Grant/Award Number: 202224093; Clinical Key Project of Peking University Third Hospital, Grant/ Award Number: Y7649305; Talent Incubation Fund of Peking University Third Hospital, Grant/Award Number: Y7649306 Abstract Background: Due to general unavailability and common side effects of tetracycline, the clinical application of bismuth quadruple therapy (BQT) is greatly limited.. Whether amoxicillin can replace tetracycline in BQT remains unknown.. This study aimed to compare the eradication rate, safety and compliance between amoxicillincontaining and tetracyclinecontaining BQT as a firstline regimen for Helicobacter pylori eradication. Article Title: A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Article Snippet: Funding information This study was supported by the Key Laboratory for Helicobacter pylori Infection and Upper Gastrointestinal Diseases in Beijing (No. BZ0371), the National Natural Science Foundation of China (No. 81670605), and the Clinical Key Projects of Peking University Third Hospital (No. Y76493-05) and AstraZeneca.. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.. Abstract Background: Favorable outcomes in treating H pylori infection using “dual therapy (proton pump inhibitor and amoxicillin four times daily)” have attracted widespread attention. Article Title: Recurrence of Helicobacter pylori infection and the affecting factors: A follow-up study. Article Snippet: study Recurrence of H. pylori infection Li Ya ZHOU, Zhi Qiang SONG, Yan XUE, Xiao LI, Yan Qing LI, Jia Ming QIAN Department of Gastroenterology, Peking University Third Hospital, Beijing, Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong Province, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China Correspondence to: Li Ya ZHOU, Department of Gastroenterology, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China.. Email: zhouliya123456@163.com Conflict of interest: None.. ABSTRACT OBJECTIVE: Recurrence of Helicobacter pylori (H. pylori) infection weakens the protective effect and long-term prognosis of eradication. Article Title: Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Article Snippet: *Department of Gastroenterology, Peking University Third Hospital, Beijing, China, State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention, National Institute for Communicable Disease Control and Prevention, Beijing, China, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, China, Department of Gastroenterology, Qilu Hospital of Shandong University, Shandong, China, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China Article Title: Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial Article Snippet: A Article Title: Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial Article Snippet: Methods The Optimizing Early Enteral Nutrition in Severe Stroke (OPENS) study was a multicentre, investigatorinitiated, prospective, open-label, randomised controlled trial, with blinded outcome assessment, in 16 tertiary and district general hospitals in the west of China.. Adult patients with acute severe ischaemic or haemorrhagic stroke (Glasgow Coma Scale score ≤12 or National Institutes of Health Stroke Scale score ≥11 on admission) who were expected to receive enteral nutrition for more than 7 days were randomly assigned (1:1:1) to full enteral nutrition (70–100% of estimated caloric requirements), modified full enteral nutrition (full enteral nutrition plus prokinetic agents), or hypocaloric enteral nutrition (40–60% of estimated caloric requirements) via a centralised web-based randomisation system.. The assigned nutrition was initiated within 24 h after enrolment and continued for 7 days. Generated:Article Title: Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Number: 82170562; Capital's Funds for Health Improvement and Research, Grant/Award Number: 202224093; Clinical Key Project of Peking University Third Hospital, Grant/ Award Number: Y7649305; Talent Incubation Fund of Peking University Third Hospital, Grant/Award Number: Y7649306 Abstract Background: Due to general unavailability and common side effects of tetracycline, the clinical application of bismuth quadruple therapy (BQT) is greatly limited.. Whether amoxicillin can replace tetracycline in BQT remains unknown.. This study aimed to compare the eradication rate, safety and compliance between amoxicillincontaining and tetracyclinecontaining BQT as a firstline regimen for Helicobacter pylori eradication. Article Title: A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Article Snippet: Funding information This study was supported by the Key Laboratory for Helicobacter pylori Infection and Upper Gastrointestinal Diseases in Beijing (No. BZ0371), the National Natural Science Foundation of China (No. 81670605), and the Clinical Key Projects of Peking University Third Hospital (No. Y76493-05) and AstraZeneca.. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.. Abstract Background: Favorable outcomes in treating H pylori infection using “dual therapy (proton pump inhibitor and amoxicillin four times daily)” have attracted widespread attention. Article Title: Recurrence of Helicobacter pylori infection and the affecting factors: A follow-up study. Article Snippet: study Recurrence of H. pylori infection Li Ya ZHOU, Zhi Qiang SONG, Yan XUE, Xiao LI, Yan Qing LI, Jia Ming QIAN Department of Gastroenterology, Peking University Third Hospital, Beijing, Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong Province, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China Correspondence to: Li Ya ZHOU, Department of Gastroenterology, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China.. Email: zhouliya123456@163.com Conflict of interest: None.. ABSTRACT OBJECTIVE: Recurrence of Helicobacter pylori (H. pylori) infection weakens the protective effect and long-term prognosis of eradication. Article Title: Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Article Snippet: *Department of Gastroenterology, Peking University Third Hospital, Beijing, China, State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention, National Institute for Communicable Disease Control and Prevention, Beijing, China, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, China, Department of Gastroenterology, Qilu Hospital of Shandong University, Shandong, China, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China Article Title: Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial Article Snippet: A Article Title: Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial Article Snippet: Methods The Optimizing Early Enteral Nutrition in Severe Stroke (OPENS) study was a multicentre, investigatorinitiated, prospective, open-label, randomised controlled trial, with blinded outcome assessment, in 16 tertiary and district general hospitals in the west of China.. Adult patients with acute severe ischaemic or haemorrhagic stroke (Glasgow Coma Scale score ≤12 or National Institutes of Health Stroke Scale score ≥11 on admission) who were expected to receive enteral nutrition for more than 7 days were randomly assigned (1:1:1) to full enteral nutrition (70–100% of estimated caloric requirements), modified full enteral nutrition (full enteral nutrition plus prokinetic agents), or hypocaloric enteral nutrition (40–60% of estimated caloric requirements) via a centralised web-based randomisation system.. The assigned nutrition was initiated within 24 h after enrolment and continued for 7 days. |